FOR IMMEDIATE RELEASE Leading non-profit and commercial organizations in psychedelic science united in visions to heal mental health conditions Donation is from atai Impact, the philanthropic arm of mental …
Patient Bills of Rights are made available to patients in various settings across the mental health and medical fields to communicate clearly with patients about what they can expect from professionals …
FOR IMMEDIATE RELEASE Independent members will inform continual iteration and improvement of ethical governance of MDMA-assisted therapy research and therapist training program Independent Ethical Review …
FOR IMMEDIATE RELEASE MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021 The designation is intended to accelerate …
FOR IMMEDIATE RELEASE On January 19, 2022, the Multidisciplinary Association for Psychedelic Studies (MAPS) and its wholly owned drug-development subsidiary MAPS Public Benefit Corporation (MAPS PBC) entered …
Download this entire issue (Large Size / Reduced Size) or browse individual articles by title below. About the Cover Artist, Catherine Nelson Psychedelic Science From the Desk of Rick Doblin, Ph.D. Rick …
Written by Mitchell Gomez MAPS Bulletin 2021, Volume 31, No. 3 Editor’s note: This article is slated for publication in the upcoming issue of the MAPS Bulletin. We have elected to publish it today, …
Psyche Unbound: Essays in Honor of Stanislav Grof is an extraordinary compilation of twenty-two essays that honor the path-breaking lifework of Stanislav Grof, M.D., Ph.D., the world’s leading researcher …
Revenue share payments will be based on North America sales of MDMA for use in MDMA-assisted therapy, will terminate after 8 years, and include a reciprocity payment structure that reduces payments once …
MAPS is honored to announce the election of Carl L. Hart, Ph.D., to MAPS’ Board of Directors, effective as of October 22, 2021. to MAPS’ Board of Directors, effective as of October 22, 2021. Dr. Carl …
On October 4, 2021, Dr. Anne Wagner and a team of researchers at Remedy Institute in Toronto, Ontario, Canada, began studying MDMA-assisted cognitive processing therapy (CPT) for individuals with posttraumatic …
After 31 years since MAPS first tried to start research into MDMA-assisted therapy for PTSD inside the Veterans Affairs (VA) system, the first study participant has been enrolled in an investigator-initiated …
